Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human umbilical cord mesenchymal stem cell therapy for acute respiratory distress syndrome
ISRCTN47911040Phase 2Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Apr 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord derived mesenchymal stem cells in acute respiratory distress syndrome (ARDS) (3 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoints: In-hospital mortality and 30-day mortality. Started Apr 2020; status: recruiting.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ISRCTN47911040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN47911040.